SCHEMBL3461681

SCHEMBL3461681

CN(C)Cc1cnccn1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.45
CHRNA4 P43681 2/20 0.45
CYP2C19 P33261 3/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
POLB P06746 1/20 0.41
GBA1 P04062 1/20 0.40
HRH1 P35367 8/20 0.39
CYP2D6 P10635 8/20 0.39
KCNH2 Q12809 5/20 0.39
CHRM1 P11229 1/20 0.39
HTR2A P28223 1/20 0.39
CYP2A6 P11509 3/20 0.37
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSP90AA1 P07900 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20882979 0.86 GAA (0.45) CHRNB2CHRNA4CYP2C19CYP1A2CYP3A4
SCHEMBL3461677 0.83 CYP3A4 (0.42) CHRNB2CHRNA4CYP2C19CYP1A2CYP3A4
SCHEMBL16741951 0.81 CYP1A2 (0.47) CYP2C19CYP1A2CYP3A4CYP2C9POLB
SCHEMBL12089147 0.79 CYP3A4 (0.41) CHRNB2CHRNA4CYP2C19CYP1A2CYP3A4
SCHEMBL14067071 0.79 POLB (0.44) CHRNB2CHRNA4CYP2C19CYP1A2CYP3A4
SCHEMBL2491068 0.78 HRH1 (0.50) CHRNB2CHRNA4CYP2C19CYP1A2CYP3A4
SCHEMBL5772725 0.78 CYP1A2 (0.40) CYP2C19CYP1A2CYP3A4CYP2C9POLB
SCHEMBL3320948 0.77 TDP1 (0.52) CYP2C19CYP1A2CYP3A4CYP2C9POLB
Trimethylammonium SCHEMBL27628866 0.77 POLB (0.41) CHRNB2CHRNA4CYP2C19CYP1A2CYP3A4
SCHEMBL19210477 0.77 TDP1 (0.44) CYP2C19CYP1A2CYP3A4CYP2C9POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203048-A1 SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-06-29 US disclosed
WO-2020125615-A1 C-TERMINAL SRC KINASE INHIBITORS INVENTISBIO SHANGHAI LTD. (CN) 2020-06-25 WO disclosed
EP-2470012-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-11-05 EP disclosed
US-8580812-B2 Heteroaryl amide analogues as P2X7 antagonists H. LUNDBECK A/S (DK) 2013-11-12 US disclosed
US-20120225886-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-09-06 US disclosed
US-20100266509-A1 HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS H. Lindbeck A/S (DK) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203048-A1 SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, PKD1 CHRNB2 4842/4885CHRNA4 4348/4885CYP2C19 177/4885
US-20120225886-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CHRNB2 43/4885CHRNA4 48/4885CYP2C19 951/4885
US-20100266509-A1 HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS P2RX7, P2RX3, P2RX2 CHRNB2 396/4885CHRNA4 430/4885CYP2C19 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.